Groenman, Annabeth P.
Schweren, Lizanne J. S.
Weeda, Wouter
Luman, Marjolein
Noordermeer, Siri D. S.
Heslenfeld, Dirk J.
Franke, Barbara
Faraone, Stephen V.
Rommelse, Nanda
Hartman, Catharina A.
Hoekstra, Pieter J.
Buitelaar, Jan
Oosterlaan, Jaap
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01MH62873)
Netherlands Organization for Scientific Research (1750102007010)
Netherlands organization for Health Research and Development (113202005)
Article History
Received: 27 October 2017
Accepted: 22 January 2019
First Online: 5 February 2019
Compliance with ethical standards
:
: In the past year, Dr. Faraone received income, potential income, reimbursement for travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax and NeuroLifeSciences. In previous years, he received income or research support from: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i>, Oxford University Press: <i>Schizophrenia: The Facts</i> and Elsevier, <i>ADHD: Non</i>-<i>Pharmacologic Interventions</i>. Dr. Hoekstra reports grants and personal fees from Shire, outside the submitted work; Dr. Buitelaar reports personal fees from Lilly, Janssen Cilag, Lundbeck, Shire and Servier, all outside the submitted work; Dr. Oosterlaan reports grants from Shire pharmaceuticals, outside the submitted work. The other authors have no financial relationships relevant to this work to disclose. Dr. Faraone, with his institution, he has US patent US20130217707 A1 for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. The other authors have no potential conflicts of interest relevant to this work to disclose.